Table 3 Risk indicators for CVD: comparison for before v. after PEG There were small numbers of participants and changes for most markers did not reach statistical significance
|  | Sesmilo 2002[9]§ n = 26 | Colao 2006[16] n = 16 | Parkinson 2002 [22]†n = 20 | Parkinson 2002 [22]†n = 20 | Paisley 2006 [13]* n = 20 |
|---|---|---|---|---|---|
PARAMETER | Mean change from baseline P | Paired t test Before v. after Tx P | Paired t test Before v. after Tx P | Cases: Before Tx v. after Tx P | Cases before Tx v. Healthy controls P |
Total chol (mM) | 0.22 NS | NS | Increased <0.01 | Increased <0.01 | 0.16 |
HDL chol (mM) | 0.006 NS | Increased 0.0017 | NS | -- | -- |
LDL chol (mM) | -0.13 NS | -- | Increased <0.01 | -- | -- |
[Total/HDL] chol | 0.21 NS | Reduced 0.0012 | -- | -- | -- |
TG (mM) | 0.25 0.007 | NS | NS | 0.3 | 0.13 |
Lipo (a) (mg/l) | -70 0.039 | -- | Reduced <0.01 | -- | -- |
Apo B | -- | -- | Increased <0.01 | -- | -- |
Apo A1 | -- | -- | Increased <0.05 | -- | -- |
Homocysteine (?M) | -0.16 NS | -- | -- | -- | -- |
CRP | 2 0.0002 | -- | -- | -- | -- |
Interleucin 6 | 0.17 NS | -- | -- | -- | -- |
Blood pressure | -- | NS | -- | -- | -- |
Fibrinogen | -- | NS | -- | -- | -- |
Heart rate | -- | NS | -- | -- | -- |
MMP-2 (ng/ml) | -- | -- | -- | Reduced <0.001 | Higher <0.001 |
MMP-9 | -- | -- | -- | 0.76 | 0.87 |
VEGF | -- | -- | -- | Reduced 0.008 | 0.18 |